Outcomes
death
ADVERSE EVENT
All-cause hospitalization or death through Day 29 and virologic outcomes with molnupiravir and placebo in immunocompromised and non-immunocompromised participants were assessed in the modified intent-to-treat population (MITT, all randomized participants who received ≥ 1 dose of study drug and were not hospitalized prior to the first dose). Adverse events through Day 29 were summarized in the safety population (all randomized participants who received ≥ 1 dose of study drug). Virologic outcomes included mean change from baseline in quantitative SARS-CoV-2 RNA over time, proportion of participants with detectable infectious SARS-CoV-2 over time, SARS-CoV-2 nucleotide error rates at Day 5, treatment-emergent amino acid changes through Day 29, proportion of participants with SARS-CoV-2 nucleocapsid antibody positivity over time, and mean change from baseline in SARS-CoV-2 neutralizing antibody titers on Days 10 and 29.